News

Genticel bags €18.2m
Enlarge image

BusinessFranceGermany

Genticel bags €18.2m

26.04.2013 - French vaccine specialist Genticel SA (Toulouse) has raised €18.2m in a financing round.

The round was led by Wellington Partners (Munich), which included all current institutional investors  such as IDInvest Partners, Edmond de Rothschild Investment Partners (Paris), InnoBio fund, IRDI and Amundi Private Equity Funds.   The company said it will use the new funds to push its two therapeutic vaccine candidates against the cancer-causing human papilloma virus subtypes HPV16 and HPV18.

Its ProCervix vaccine, which is built on Genticel’s CyaA antigen delivery technology, has successfully finished phase I clinical study. The phase I trial (n=47) revealed no dose limiting toxicity and no patient drop-out. In addition, ProCervix induced a dose-dependent immune response as well as viral clearance in a substantially larger percentage of patients as compared to placebo. ProCervix will enter into phase II development in order to demonstrate proof of efficacy. Genticel’s other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.    Currently, there is preventive HPV vaccination but still no effective treatment against established infection with high-risk HPV types albeit promising approaches.

Genticel’s vaccines are designed for the treatment of infected women who have not yet developed high-grade cervical lesions or cancer.    Recent estimates by the World Health Organization suggest that world-wide approximately 300 million women are carriers of HPV infection at any given time and approximately 500,000 patients are diagnosed with cervical cancer each year.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/genticel-bags-eur182m.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SCANCELL HOLDINGS (UK)29.25 GBP7.93%
  • CELLECTIS (F)32.30 EUR7.31%
  • ALMIRALL (E)17.87 EUR7.26%

FLOP

  • TRANSGENE (F)3.99 EUR-14.56%
  • BAVARIAN NORDIC (D)39.72 EUR-5.61%
  • EUROFINS SCIENTIFIC (F)255.00 EUR-5.39%

TOP

  • PROTHENA PLC (IE)52.67 USD31.8%
  • VERONA PHARMA (UK)5.20 GBP22.4%
  • DBV Technologies (F)51.87 EUR21.8%

FLOP

  • OREXO (S)68.00 SEK-24.7%
  • NORDIC NANOVECTOR (N)26.90 NOK-23.6%
  • SCANCELL HOLDINGS (UK)29.25 GBP-23.5%

TOP

  • ADOCIA (F)67.19 EUR387.9%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.64 EUR343.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.60 SEK-70.3%
  • NEOVACS (F)1.12 EUR-67.0%

No liability assumed, Date: 30.06.2015